Business
Amphastar is a pharmaceutical company that develops, manufactures, and sells products including Baqsimi, Primatene Mist, epinephrine, glucagon, lidocaine, and other medicines.
Amphastar revenue slipped 1.7% to $719.9M, net income fell 38.5%, and free cash flow fell 29.7%.
The read at a glance✓ Audited against SEC data
- Business mix — Pharmaceutical products and devicesNote
- Revenue — Revenue fell 1.7% to $719.9MWatch
- Profitability — Net income fell 38.5%Watch
- Cash — Free cash flow fell 29.7%Watch
- Balance sheet — Debt rose 1.0%; equity rose 7.7%Note
- Insiders — 0 buys / 9 sellsWatch
- Accounting — Altman-Z grey; EQ safeNote
Where the revenue comes from
Fiscal 2025, as Amphastar Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Product$719.9M
- Research and development services$3.2M
Latest filings
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-07-13
- 8-K · Company announcement2026-07-08
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Amphastar Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.